SCHEMBL13256288

SCHEMBL13256288

CC(C)(C)c1n[nH]c2nc(NC(=O)c3ccccc3)sc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
PKM P14618 1/20 0.52
ALDH1A1 P00352 5/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.49
KDM4E B2RXH2 2/20 0.48
HCRTR1 O43613 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP2C9 P11712 1/20 0.47
TP53 P04637 1/20 0.47
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
LMNA P02545 1/20 0.46
SCD O00767 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13256292 0.89 SMN1; SMN2 (0.60) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL13256165 0.83 NPC1 (0.63) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL14454844 0.81 NPC1 (0.54) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL14454809 0.80 NPC1 (0.52) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL3501713 0.75 ADORA2A (0.60) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL3500983 0.75 MAPT (0.61) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL13256284 0.75 F2 (0.54) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL77592 0.74 SMN1; SMN2 (0.77) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL13256173 0.74 PTGDR2 (0.61) NPC1RAB9APKMALDH1A1KMT2A
SCHEMBL13256183 0.74 MAPK14 (0.54) NPC1RAB9APKMALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS MAP3K20, MAP4K2, MAP4K3 NPC1 2951/4885RAB9A 1601/4885PKM 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.